義大醫院藥品外觀辨識 暨 處方集 內容
藥品外觀
處方集
目前暫無圖片
藥品代碼:KVENET3
廠商: 艾伯維
規格: 100mg/tab
顏色:黃色
形狀:橢圓形
劑型:
標記:
健保碼:BC27359100
ATC code:L01XX52
學名
Venetoclax
商品名
Venclexta
中文名
唯可來膜衣錠
規格含量
100mg/tab; 120tab/bot
藥理分類
04. ANTINEOPLASTIC AGENTS; ;
04.09. MISCELLANEOUS;;
藥理作用
Antineoplastic Agent, BCL-2 Inhibitor
適應症(藥袋)
標靶藥物
懷孕分級
D 已證實對人之胎兒有傷害,若是疾病對於孕婦有生命威脅或安全的藥品已無法治療的情況下,權衡利弊,仍可使用。
授乳安全性
Unknown
用法用量
Acute myeloid leukemia(AML), newly diagnosed
Ramp up dosage: 100 mg PO on day 1, 200 mg on day 2, and 400 mg on day 3
Usual dosage: beginning on day 4, 400 mg PO once daily when given with azacitidine or decitabine or 600 mg once daily when given with low-dose cytarabine
Chronic lymphoid leukemia(CLL)
Ramp-up dosage: 20 mg PO once daily during week 1; 50 mg once daily during week 2; 100 mg once daily during week 3; 200 mg once daily during week 4, then 400 mg once daily during week 5.
(1)Monotherapy: after completion of 5-week ramp-up schedule, 400 mg orally once daily until disease progression or unacceptable toxicity.
(2)Combination with obinutuzumab: start obinutuzumab at 100 mg on cycle 1 day 1, followed by 900 mg on cycle 1 day 2; administer 1000 mg on days 8 and 15 of cycle 1, followed by 1000 mg on day 1 of each subsequent 28-day cycle, for a total of 6 cycles; on cycle 1 day 22, start venetoclax according to the 5-week ramp-up schedule until cycle 2 day 28; continue venetoclax 400 mg orally once daily from cycle 3 day 1 until the last day of cycle 12.
(3)Combination with rituximab: start rituximab after completion of the 5-week venetoclax dose ramp-up schedule and patient has received the venetoclax 400 mg dose for 7 days; give rituximab on day 1 of each 28-day cycle for 6 cycles, with rituximab 375 mg/m(2) IV for cycle 1 and 500 mg/m2 IV for cycles 2 to 6; continue venetoclax 400 mg once daily for 24 months from cycle 1, day 1 of rituximab.
副作用
Leukopenia, diarrhea, upper respiratory tract infection, cough, nausea
禁忌
開始治療或劑量調整期間,由於可能會增加腫瘤溶解症候群的風險,CLL病人禁止併用強效CYP3A抑制劑
停用抑制劑2-3天之後,請恢復Venclexta在使用強效或中效CYP3A抑制劑或P-gp抑制劑之前的劑量
注意事項
1.用藥2天前和整個劑量調整期間,每天都飲用大量的水(約6-8杯,1.6L/天),以降低腫瘤溶解症候群風險
2.漏服藥品:應於服藥時間8小時內盡快服藥
3.藥品應整粒吞服,不可咀嚼、咬碎或剝開
4.考量病人特異性因素,以評估腫瘤溶解症候群的風險高低的程度,並在本品第一劑治療前,預防性補充水分及施用降尿酸藥物
5.有生育能力的女性,在本品療期間到最後一劑之後至少30天內,應採用有效避孕措施
藥品與食物交互作用
服藥期間避免食用葡萄柚或葡萄柚汁、苦橙、楊桃
建立者
103617
建立時間
2020-09-03 15:14:45
維護者
103617
維護時間
2023-04-24 14:37:05

義大醫院 諮詢專線:07-6150011轉2000